Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

PaperCitations, authors & open-access status

Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 2,360 citations, 1999 year and closed oa status.

2,360
Citations
1999
Year
closed
OA Status

Related on ScholarIQ

Peter E. Lipsky
Author
The Lancet
Journal
Rheumatoid Arthritis Research and Therapies
Topic
Rheumatoid Arthritis Research and Therapies
Topic
Autoimmune and Inflammatory Disorders Research
Topic
Monoclonal and Polyclonal Antibodies Research
Topic
470M+ articles · free account